68016-154 NDC - NIGHT TIME SEVERE COLD AND COUGH RELIEF (ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCL)

Drug Information

Product NDC: 68016-154

Proprietary Name: Night Time Severe Cold and Cough Relief

Non Proprietary Name: ACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCL

Active Ingredient(s):
  • 325 mg/15mL ACETAMINOPHEN;
  • 12.5 mg/15mL DIPHENHYDRAMINE HYDROCHLORIDE;
  • 5 mg/15mL PHENYLEPHRINE HYDROCHLORIDE


Administration Route(s): ORAL

Dosage Form(s): LIQUID

Pharmacy Class(es):
  • Adrenergic alpha1-Agonists [MoA];
  • Histamine H1 Receptor Antagonists [MoA];
  • Histamine-1 Receptor Antagonist [EPC];
  • alpha-1 Adrenergic Agonist [EPC]

Labeler Information

Labeler Name: Chain Drug Consortium, LLC
Product Type: HUMAN OTC DRUG
FDA Application Number: part343
Marketing Category: OTC MONOGRAPH NOT FINAL
Start Marketing Date:10/4/2013

Package Information

No. Package Code Package Description Billing Unit
168016-154-08245 mL in 1 BOTTLE (68016-154-08)ML

NDC Record

Field Name Field Value Definition
PRODUCT NDC68016-154The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN OTC DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMENight Time Severe Cold and Cough ReliefThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEACETAMINOPHEN, DIPHENHYDRAMINE HCL, PHENYLEPHRINE HCLThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMELIQUIDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE10/4/2013This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEOTC MONOGRAPH NOT FINALProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERpart343This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEChain Drug Consortium, LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEACETAMINOPHEN; DIPHENHYDRAMINE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDEAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH325; 12.5; 5 
ACTIVE INGRED UNITmg/15mL; mg/15mL; mg/15mL 
PHARM CLASSESAdrenergic alpha1-Agonists [MoA], Histamine H1 Receptor Antagonists [MoA], Histamine-1 Receptor Antagonist [EPC], alpha-1 Adrenergic Agonist [EPC] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023